What are SLC7A11 antibodies?
Anti-SLC7A11 antibodies are immunoglobulins that specifically recognize and bind SLC7A11, the gene encoding the cystine/glutamate transporter in humans. In research applications, these antibodies are used to detect SLC7A11 in tissue samples, cell lysates, and cultured cells. SLC7A11 partners with SLC3A2 to exchange extracellular cystine for intracellular glutamate, supplying the cysteine needed for glutathione synthesis and protecting cells from oxidative stress. Because SLC7A11 activity suppresses ferroptosis, a form of iron-dependent cell death, it is a prominent target in cancer metabolism research.
Catalog highlights and purchasing considerations
About the Biocompare SLC7A11 antibody catalog
The Biocompare antibody search tool lists SLC7A11 antibodies from a wide range of suppliers, with western blot, immunohistochemistry, and flow cytometry among the most common validated applications. Listings may also appear under the gene symbol SLC7A11 or the common name xCT, an earlier designation for the same transporter. Several SLC7A11 antibodies mentioned here have been cited across a range of cancer research, including studies on UCHL5-mediated ZRANB1 stabilization suppressing thyroid carcinoma progression through ferroptosis regulation, NSUN2-mediated m5C methylation inhibiting ferroptosis in breast cancer, and OTUD5-mediated SLC7A11 stabilization suppressing ferroptosis in acute myeloid leukemia.
Considerations when choosing an SLC7A11 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.